Cowen & Co. Maintains a Hold Rating on Miragen Therapeutics Inc

By Jason Carr

Cowen & Co. analyst Ritu Baral maintained a Hold rating on Miragen Therapeutics Inc (NASDAQ: MGEN) on April 6. The company’s shares closed on Friday at $6.50, close to its 52-week low of $5.01.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 29.2% and a 52.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Global Blood Therapeutics, and Intra-Cellular Therapies.

Miragen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $16.50.

Based on Miragen Therapeutics Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $1.19 million and GAAP net loss of $6.39 million. In comparison, last year the company earned revenue of $462K and had a GAAP net loss of $6.99 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates, MRG-106 focuses on the treatment of cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth on February 13, 2007 and is headquartered in Boulder, CO.